Summary: Central serous chorioretinitis is a relatively common eye condition. It is a maculopathy of the young subject, characterized by the presence of a retinal serous detachment, usually located at the posterior pole, associated with changes in the pigment epithelium. Materials and methods: a prospective study was conducted between Mars 2018 and Mars 2020 at the Mohammed V military hospital in Rabat, in 11 patients treated with eplerenone for a chronic CRSC evolving for at least 3 months with repercussions on visual acuity, at the dose of 25 mg per day the first week, then 50 mg per day for an average treatment duration of 15 weeks. For each patient, visual acuity and macular OCT (central thickness of the retina) were evaluated before treatment and at 1, 3 and 6 months. Results: The mean age of the patients was 32,54 ± 6,78. 11 men. All patients were under stress, and just two patient reported the notion of taking corticosteroids. The average duration of progression of the pathology before treatment was 20 weeks. A clear improvement in visual acuity (logMAR) was observed in 9 patients: mean visual acuity increased from 0,7 at admission to 0,69 at 1 month (p: 0.014), 0,4 at 3 months (p: 0.013) and 0,28 at 6 months (p: 0.025). The mean central macular thickness decreased from 423 ± 91 μm before treatment, 317 ± 82 μm at 1 month and 292 ± 73,6 μm at 3 months and 251± 94 μm at 6 months (p 0.026, 0.01 and 0.038 respectively). 5 patients had a complete disappearance of SRF at 3 months. 1 other patients had a complete disappearance of the DSR at 6 months. The treatment was stopped for 3 patients, including 1 at 4 weeks for severe muscle cramps, and hyperkaliema for the 2 others at 10 weeks ans 11 weeks of treatment. Conclusion: In our study, the introduction of eplerenone resulted in significant improvement in both anatomical and functional outcomes in patients with chronic CSCR.
| Published in | International Journal of Ophthalmology & Visual Science (Volume 5, Issue 2) |
| DOI | 10.11648/j.ijovs.20200502.16 |
| Page(s) | 66-69 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2020. Published by Science Publishing Group |
Chronic Central Serous Chorioretinitis, Eplerenone, Sub-retinal Fluid, Mineralocorticoid Receptor
| [1] | Summary: Central serous chorioretinitis is a relatively common eye condition. It is a maculopathy of the young subject, characterized by the presence of a retinal serous detachment, usually located at the posterior pole, associated with changes in the pigment epithelium. Materials and methods: a prospective study was conducted between Mars 2018 and Mars 2020 at the Mohammed V military hospital in Rabat, in 11 patients treated with eplerenone for a chronic CRSC evolving for at least 3 months with repercussions on visual acuity, at the dose of 25 mg per day the first week, then 50 mg per day for an average treatment duration of 15 weeks. For each patient, visual acuity and macular OCT (central thickness of the retina) were evaluated before treatment and at 1, 3 and 6 months. Results: The mean age of the patients was 32,54 ± 6,78. 11 men. All patients were under stress, and just two patient reported the notion of taking corticosteroids. The average duration of progression of the pathology before treatment was 20 weeks. A clear improvement in visual acuity (logMAR) was observed in 9 patients: mean visual acuity increased from 0,7 at admission to 0,69 at 1 month (p: 0.014), 0,4 at 3 months (p: 0.013) and 0,28 at 6 months (p: 0.025). The mean central macular thickness decreased from 423 ± 91 μm before treatment, 317 ± 82 μm at 1 month and 292 ± 73,6 μm at 3 months and 251± 94 μm at 6 months (p 0.026, 0.01 and 0.038 respectively). 5 patients had a complete disappearance of SRF at 3 months. 1 other patients had a complete disappearance of the DSR at 6 months. The treatment was stopped for 3 patients, including 1 at 4 weeks for severe muscle cramps, and hyperkaliema for the 2 others at 10 weeks ans 11 weeks of treatment. Conclusion: In our study, the introduction of eplerenone resulted in significant improvement in both anatomical and functional outcomes in patients with chronic CSCR. |
APA Style
Mehdi Khamaily, Joumany Brahim Salem, Imane Tarib, Wafaa Akioud, Soukaina Haddougui, et al. (2020). Eplerenone in the Central Serous Chorioretinopathy Chronic. International Journal of Ophthalmology & Visual Science, 5(2), 66-69. https://doi.org/10.11648/j.ijovs.20200502.16
ACS Style
Mehdi Khamaily; Joumany Brahim Salem; Imane Tarib; Wafaa Akioud; Soukaina Haddougui, et al. Eplerenone in the Central Serous Chorioretinopathy Chronic. Int. J. Ophthalmol. Vis. Sci. 2020, 5(2), 66-69. doi: 10.11648/j.ijovs.20200502.16
AMA Style
Mehdi Khamaily, Joumany Brahim Salem, Imane Tarib, Wafaa Akioud, Soukaina Haddougui, et al. Eplerenone in the Central Serous Chorioretinopathy Chronic. Int J Ophthalmol Vis Sci. 2020;5(2):66-69. doi: 10.11648/j.ijovs.20200502.16
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.ijovs.20200502.16,
author = {Mehdi Khamaily and Joumany Brahim Salem and Imane Tarib and Wafaa Akioud and Soukaina Haddougui and Yassine Mouzari and Fouad El Asri and Karim Reda and Abdelbarre Oubaaz},
title = {Eplerenone in the Central Serous Chorioretinopathy Chronic},
journal = {International Journal of Ophthalmology & Visual Science},
volume = {5},
number = {2},
pages = {66-69},
doi = {10.11648/j.ijovs.20200502.16},
url = {https://doi.org/10.11648/j.ijovs.20200502.16},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijovs.20200502.16},
abstract = {Summary: Central serous chorioretinitis is a relatively common eye condition. It is a maculopathy of the young subject, characterized by the presence of a retinal serous detachment, usually located at the posterior pole, associated with changes in the pigment epithelium. Materials and methods: a prospective study was conducted between Mars 2018 and Mars 2020 at the Mohammed V military hospital in Rabat, in 11 patients treated with eplerenone for a chronic CRSC evolving for at least 3 months with repercussions on visual acuity, at the dose of 25 mg per day the first week, then 50 mg per day for an average treatment duration of 15 weeks. For each patient, visual acuity and macular OCT (central thickness of the retina) were evaluated before treatment and at 1, 3 and 6 months. Results: The mean age of the patients was 32,54 ± 6,78. 11 men. All patients were under stress, and just two patient reported the notion of taking corticosteroids. The average duration of progression of the pathology before treatment was 20 weeks. A clear improvement in visual acuity (logMAR) was observed in 9 patients: mean visual acuity increased from 0,7 at admission to 0,69 at 1 month (p: 0.014), 0,4 at 3 months (p: 0.013) and 0,28 at 6 months (p: 0.025). The mean central macular thickness decreased from 423 ± 91 μm before treatment, 317 ± 82 μm at 1 month and 292 ± 73,6 μm at 3 months and 251± 94 μm at 6 months (p 0.026, 0.01 and 0.038 respectively). 5 patients had a complete disappearance of SRF at 3 months. 1 other patients had a complete disappearance of the DSR at 6 months. The treatment was stopped for 3 patients, including 1 at 4 weeks for severe muscle cramps, and hyperkaliema for the 2 others at 10 weeks ans 11 weeks of treatment. Conclusion: In our study, the introduction of eplerenone resulted in significant improvement in both anatomical and functional outcomes in patients with chronic CSCR.},
year = {2020}
}
TY - JOUR T1 - Eplerenone in the Central Serous Chorioretinopathy Chronic AU - Mehdi Khamaily AU - Joumany Brahim Salem AU - Imane Tarib AU - Wafaa Akioud AU - Soukaina Haddougui AU - Yassine Mouzari AU - Fouad El Asri AU - Karim Reda AU - Abdelbarre Oubaaz Y1 - 2020/06/17 PY - 2020 N1 - https://doi.org/10.11648/j.ijovs.20200502.16 DO - 10.11648/j.ijovs.20200502.16 T2 - International Journal of Ophthalmology & Visual Science JF - International Journal of Ophthalmology & Visual Science JO - International Journal of Ophthalmology & Visual Science SP - 66 EP - 69 PB - Science Publishing Group SN - 2637-3858 UR - https://doi.org/10.11648/j.ijovs.20200502.16 AB - Summary: Central serous chorioretinitis is a relatively common eye condition. It is a maculopathy of the young subject, characterized by the presence of a retinal serous detachment, usually located at the posterior pole, associated with changes in the pigment epithelium. Materials and methods: a prospective study was conducted between Mars 2018 and Mars 2020 at the Mohammed V military hospital in Rabat, in 11 patients treated with eplerenone for a chronic CRSC evolving for at least 3 months with repercussions on visual acuity, at the dose of 25 mg per day the first week, then 50 mg per day for an average treatment duration of 15 weeks. For each patient, visual acuity and macular OCT (central thickness of the retina) were evaluated before treatment and at 1, 3 and 6 months. Results: The mean age of the patients was 32,54 ± 6,78. 11 men. All patients were under stress, and just two patient reported the notion of taking corticosteroids. The average duration of progression of the pathology before treatment was 20 weeks. A clear improvement in visual acuity (logMAR) was observed in 9 patients: mean visual acuity increased from 0,7 at admission to 0,69 at 1 month (p: 0.014), 0,4 at 3 months (p: 0.013) and 0,28 at 6 months (p: 0.025). The mean central macular thickness decreased from 423 ± 91 μm before treatment, 317 ± 82 μm at 1 month and 292 ± 73,6 μm at 3 months and 251± 94 μm at 6 months (p 0.026, 0.01 and 0.038 respectively). 5 patients had a complete disappearance of SRF at 3 months. 1 other patients had a complete disappearance of the DSR at 6 months. The treatment was stopped for 3 patients, including 1 at 4 weeks for severe muscle cramps, and hyperkaliema for the 2 others at 10 weeks ans 11 weeks of treatment. Conclusion: In our study, the introduction of eplerenone resulted in significant improvement in both anatomical and functional outcomes in patients with chronic CSCR. VL - 5 IS - 2 ER -
Information
Email: